<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334971</url>
  </required_header>
  <id_info>
    <org_study_id>2002-P-001354</org_study_id>
    <secondary_id>Sundry</secondary_id>
    <nct_id>NCT00334971</nct_id>
  </id_info>
  <brief_title>Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women</brief_title>
  <official_title>Aromatase Activity and Ovarian Growth Factors in Preovulatory Follicles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to understand how the ovarian follicle (the fluid filled
      structure in the ovary that contains the egg) makes estrogen and other hormones during normal
      aging, in women with different ethnic backgrounds, and in Fragile X premutation carriers.

      During reproductive aging, estradiol levels are increased, a phenomenon that may be related
      to increased aromatase activity. The investigators' own preliminary data suggest that
      estradiol is increased in African-American women compared to Caucasian women, which may also
      be related to aromatase activity. In addition, the investigators have examined female fragile
      X premutation carriers who still have regular menstrual cycles and have demonstrated evidence
      of early ovarian aging compared to age-matched controls.

      **WE ARE RECRUITING ONLY WOMEN WITH FRAGILE-X PREMUTATION**
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to examine intrafollicular changes in aromatase and ovarian
      growth factors in reproductive aged women,African-American women compared to Caucasian
      controls, and Fragile X premutation carriers.

      Hypotheses:

        -  Aromatase activity is up-regulated in preovulatory follicles with aging, accounting for
           the increased estradiol levels in the face of decreased inhibin secretion in
           reproductive aging.

        -  Increased estradiol in the face of normal inhibin A and inhibin B suggests up-regulation
           of aromatase in African-American women.

        -  Aromatase activity is down-regulated in preovulatory follicles in fragile X premutation
           carriers compared to age-matched controls and the activity is associated with FMR1 mRNA
           levels.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2004</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum androstenedione, E2, A/E2, inhibin A, and inhibin B</measure>
    <time_frame>at first day of menses until day after aspiration procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Follicular fluid androstenedione, E2, A/E2, inhibin A, and inhibin B</measure>
    <time_frame>after aspiration procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RT-PCR results for aromatase in aspirated follicular fluid, when follicle is &gt; 14 mm</measure>
    <time_frame>after aspiration procedure</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Healthy</condition>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Caucasian women 18-35 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy African-American women 18-35 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Caucasian women 36-45 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Female fragile X premutation carriers 18-45 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Follicle Aspiration</intervention_name>
    <description>Follicles will be aspirated using a transvaginal ultrasound guided needle.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Reproductively Younger Non-African-American Women:

          -  18-35 years of age

          -  Body mass index (BMI) less than or equal to 30

          -  Regular menstrual cycles (25-35 days long)

          -  Negative beta-human chorionic gonadotrophin (HCG)

          -  Normal prolactin and thyroid stimulating hormone (TSH) levels

          -  Hemoglobin greater than or equal to 11.0 gm/dl

          -  Luteal phase progesterone level indicating ovulation on a previous cycle (&gt; 3 ng/ml)

          -  Not currently trying to get pregnant

          -  No blood donations within 2 months of initiating the blood sampling portion of the
             study

          -  On no medications thought to interfere with normal menstrual cycle dynamics

          -  Not current smokers or no exposure to passive smoke in the home or workplace (greater
             than 8 hours per day with a smoker of &gt; 10 cigarettes per day)

          -  Normal platelet count and PT/PTT

          -  No history of pelvic adhesions and accessible ovarian position as assessed by
             transvaginal ultrasound

        Reproductively Younger African-American Women:

          -  18-35 years of age

          -  Meets all other inclusion criteria for the reproductively younger non-African-American
             population outlined above

        Reproductively Older Non-African-American Women:

          -  36-45 years of age

          -  Meets all other inclusion criteria for the reproductively younger non-African-American
             population outlined above.

        Reproductive Aged Fragile X Premutation Carriers

          -  Fragile X premutation carriers, with FMR1 CGG repeat lengths between 41 and 200.

          -  18-45 years of age

          -  Meets all other inclusion criteria for the reproductively younger non-African-American
             population outlined above.

        Exclusion Criteria:

          -  Hemoglobin level less than 11 gm/dl at time of screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet E Hall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Endocrine Unit, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab. 1999 Jan;84(1):105-11.</citation>
    <PMID>9920069</PMID>
  </reference>
  <reference>
    <citation>Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996 Apr;81(4):1495-501.</citation>
    <PMID>8636357</PMID>
  </reference>
  <reference>
    <citation>Reame NE, Kelche RP, Beitins IZ, Yu MY, Zawacki CM, Padmanabhan V. Age effects of follicle-stimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women. J Clin Endocrinol Metab. 1996 Apr;81(4):1512-8.</citation>
    <PMID>8636360</PMID>
  </reference>
  <reference>
    <citation>Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996 Mar;81(3):1038-45.</citation>
    <PMID>8772573</PMID>
  </reference>
  <reference>
    <citation>MacNaughton J, Banah M, McCloud P, Hee J, Burger H. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol (Oxf). 1992 Apr;36(4):339-45.</citation>
    <PMID>1424166</PMID>
  </reference>
  <reference>
    <citation>Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, Dennerstein L, Morse C. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab. 1995 Dec;80(12):3537-45.</citation>
    <PMID>8530596</PMID>
  </reference>
  <reference>
    <citation>Welt CK, Smith ZA, Pauler DK, Hall JE. Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development. J Clin Endocrinol Metab. 2001 Jun;86(6):2531-7.</citation>
    <PMID>11397851</PMID>
  </reference>
  <reference>
    <citation>Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, Taylor AE. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab. 2000 Sep;85(9):3319-30.</citation>
    <PMID>10999828</PMID>
  </reference>
  <reference>
    <citation>Khoury MJ, Erickson JD. Maternal factors in dizygotic twinning: evidence from interracial crosses. Ann Hum Biol. 1983 Sep-Oct;10(5):409-15.</citation>
    <PMID>6638936</PMID>
  </reference>
  <reference>
    <citation>KNOX G, MORLEY D. Twinning in Yoruba women. J Obstet Gynaecol Br Emp. 1960 Dec;67:981-4.</citation>
    <PMID>13757217</PMID>
  </reference>
  <reference>
    <citation>Myrianthopoulos NC. An epidemiologic survey of twins in a large, prospectively studied population. Am J Hum Genet. 1970 Nov;22(6):611-29.</citation>
    <PMID>5518457</PMID>
  </reference>
  <reference>
    <citation>Martin NG, Robertson DM, Chenevix-Trench G, de Kretser DM, Osborne J, Burger HG. Elevation of follicular phase inhibin and luteinizing hormone levels in mothers of dizygotic twins suggests nonovarian control of human multiple ovulation. Fertil Steril. 1991 Sep;56(3):469-74.</citation>
    <PMID>1894024</PMID>
  </reference>
  <reference>
    <citation>Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol. 2001 Jan 1;153(1):11-9.</citation>
    <PMID>11159140</PMID>
  </reference>
  <reference>
    <citation>Sondik EJ. Breast cancer trends. Incidence, mortality, and survival. Cancer. 1994 Aug 1;74(3 Suppl):995-9.</citation>
    <PMID>8039156</PMID>
  </reference>
  <reference>
    <citation>Perry HM 3rd, Horowitz M, Morley JE, Fleming S, Jensen J, Caccione P, Miller DK, Kaiser FE, Sundarum M. Aging and bone metabolism in African American and Caucasian women. J Clin Endocrinol Metab. 1996 Mar;81(3):1108-17.</citation>
    <PMID>8772584</PMID>
  </reference>
  <reference>
    <citation>Woods MN, Barnett JB, Spiegelman D, Trail N, Hertzmark E, Longcope C, Gorbach SL. Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst. 1996 Oct 2;88(19):1369-74.</citation>
    <PMID>8827014</PMID>
  </reference>
  <reference>
    <citation>Woods MN, Gorbach SL, Longcope C, Goldin BR, Dwyer JT, Morrill-LaBrode A. Low-fat, high-fiber diet and serum estrone sulfate in premenopausal women. Am J Clin Nutr. 1989 Jun;49(6):1179-83.</citation>
    <PMID>2543203</PMID>
  </reference>
  <reference>
    <citation>Manson JM, Sammel MD, Freeman EW, Grisso JA. Racial differences in sex hormone levels in women approaching the transition to menopause. Fertil Steril. 2001 Feb;75(2):297-304.</citation>
    <PMID>11172830</PMID>
  </reference>
  <reference>
    <citation>Welt CK, Schneyer AL. Differential regulation of inhibin B and inhibin a by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles. J Clin Endocrinol Metab. 2001 Jan;86(1):330-6.</citation>
    <PMID>11232020</PMID>
  </reference>
  <reference>
    <citation>Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF Jr, Schneyer AL. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab. 1997 Nov;82(11):3720-7.</citation>
    <PMID>9360531</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2006</study_first_submitted>
  <study_first_submitted_qc>June 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet E. Hall, MD</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>African-American</keyword>
  <keyword>estradiol</keyword>
  <keyword>luteinizing hormone</keyword>
  <keyword>follicle stimulating hormone</keyword>
  <keyword>androstenedione</keyword>
  <keyword>aromatase</keyword>
  <keyword>inhibins</keyword>
  <keyword>ovarian</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Fragile X</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

